Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL8592940 | 0.98 | CTDSP1 (0.37) | CTDSP1SMN1; SMN2 | |
| SCHEMBL4907261 | 0.85 | SMN1; SMN2 (0.36) | CTDSP1SMN1; SMN2 | |
| SCHEMBL9935984 | 0.85 | CTDSP1 (0.35) | CTDSP1 | |
| Hydrochloric Acid SCHEMBL30804526 | 0.83 | SMN1; SMN2 (0.35) | CTDSP1SMN1; SMN2 | |
| SCHEMBL31371589 | 0.83 | — | — | |
| SCHEMBL9936322 | 0.81 | HPGD (0.34) | CTDSP1 | |
| SCHEMBL18526268 | 0.81 | CTDSP1 (0.33) | CTDSP1 | |
| SCHEMBL2100281 | 0.81 | CTDSP1 (0.44) | CTDSP1 | |
| SCHEMBL575287 | 0.80 | CHRNA7 (0.37) | CTDSP1 | |
| Iodide SCHEMBL9179010 | 0.79 | CTDSP1 (0.46) | CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20170266208-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-9694020-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2016-03-31 | — | — | US | disclosed |
| EP-1867667-B1 | Method for manufacturing stabilized polyacetal resin | POLYPLASTICS CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20080271381-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | POLYPLASTICS CO., LTD (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1867667-A1 | Method for manufacturing stabilized polyacetal resin, stabilized polyacetal resin, stabilized polyacetal resin composition, and molded article of stabilized polyacetal resin | Polyplastics Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | CTDSP1 4745/4885SMN1; SMN2 1452/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | CTDSP1 4387/4885SMN1; SMN2 2005/4885 |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | CTDSP1 4387/4885SMN1; SMN2 2005/4885 |
| US-20170266208-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | CTDSP1 4387/4885SMN1; SMN2 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.